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and antidepressants
Abstract
Serotonin syndrome is potentially life-threatening syndrome associated with excessive serotonergic activity 
within the central nervous system. Serotonin syndrome is associated with medication use, drug interactions, 
and overdose. While serotonin syndrome is often associated with the use of selective serotonin inhibitors 
(SSRI), an increasing number of reports are being presented involving the use of tramadol. With tramadol 
increasing popularity, the goal of this article is to make physicians more alert and aware of this potential 
side effect. Serotonin syndrome may be difficult to diagnose. A case of serotonin syndrome caused by the 
combination of tramadol and antidepressants in a patient with advanced cancer is presented and discussed. 
The importance of early diagnosis of this syndrome is emphasized.
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Introduction
Tramadol is used for the treatment of moderate 
pain in adults. Structurally it is not an opioid but it 
binds to μ receptors. It is a prodrug metabolized by 
CYP2D6 isoenzyme of cytochrome P450 and the anal-
gesic effect results from O-demethylation whose pro-
duct is M1 [1–3]. Its opioid agonist action is combined 
with parent compound effect which is the inhibition of 
the reuptake of serotonin (5-HT) and norepinephrine.
Phenotypic variation influences the rate of accu-
mulation and elimination of the drug. This supposes 
an uncertainty of the effect that the patient is going to 
have, both in terms of efficacy as in terms of adverse 
effects. Tramadol is a substrate for the cytochrome 
P450 CYP2D6 liver enzyme, hence any agents with 
the ability to inhibit this enzyme will probably interact 
with tramadol and may intensify its adverse effects. In 
addition, genetic polymorphism of CYP2D6 may result 
in a wide spectrum of enzyme activity (phenotypes). 
At one end of the spectrum, two inactive alleles lead 
to individuals with no CYP2D6 enzyme activity, so-cal-
led poor metabolizers, which may lead to inadequate 
analgesia due to lack of formation of M1. At the other 
extreme, duplication of alleles results in individuals 
with very high CYP2D6 enzyme activity (ultrarapid 
metabolisers) that may lead to excessive adverse ef-
fects intensity [1–3].
There is a  growing amount of post-marketing 
evidence that shows risks with the consumption of 
tramadol, which should make the decision to prescribe 
this drug to be considered more carefully. Between 
1997 and 2017, 30,730 cases of adverse effects were 
reported to the FDA. If tramadol is administered with 
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drugs that inhibit CYP2D6, such as paroxetine or flu-
oxetine, a patient can pass from being an extensive 
or intermediate metabolizer to a  poor metabolizer 
with risks of developing a  serotonin syndrome [3]. 
This syndrome has high mortality and results from 
the interaction between drugs. Although classified as 
an opioid, only about 30% of tramadol activity can be 
reversed with naloxone and it is these non–opioid 
actions that set tramadol apart from other drugs. Ho-
wever, it is also the serotoninergic and noradrenergic 
effects that give tramadol its most troublesome re-
ported side–effects: sedation, lowering the convulsion 
threshold, and delirium [1, 2].
Case presentation
A 56-year-old patient with a recent diagnosis of 
stage IV pancreatic cancer with hepatic metastases 
who received paroxetine 20 mg/day and mirtazapine 
30 mg at night for treatment of a depressive syndro-
me. Five days before admission, she developed pain 
in the lower back and epigastrium, numerical rating 
scale (NRS) 6/10, and her doctor started treatment 
with tramadol 100 mg every 8 hours and paraceta-
mol 1 g every 8 hours. Three days after starting this 
treatment, her family perceived her confused, she 
had intense pain, palpitations, diarrhoea, nausea and 
profuse sweating. The pain intensity was increasing 
(NRS 9/10) and the clinical situation of delirium, pro-
fuse sweating, tachycardia and pain motivated the 
admission into a Palliative Care Unit.
At the physical examination the patient showed 
a hyperactive delirium, with CAM (confusion assess-
ment method) test positive, sweating, HR 110/ min, 
BP 170/95 mm Hg, RR 24/min, axillary temperature 
37ºC. She demonstrated generalized muscle rigidity 
with hyperreflexia in the lower extremities. Sponta-
neous and ocular clonus. Bilateral mydriasis. Normal 
cardiopulmonary auscultation. Abdomen painful, 
without peritonism. Hepatomegaly 2 cm. Analytical: 
Sodium 138 mMol/L, potassium 4 mMol/L, chloride 
94 mMol/L, creatinine 1.2 mg/dL, creatinine clearance 
60 mL/min, level 26 mcg/mL, WBC 10.5 thou/mcL, HGB 
11.0 gm/dL, MCV 101 FL, AST 60 U/L, AST 70 U/L, GGT 
120 U/ ml. Normal liver function tests. Plasma calcium 
corrected: normal. Negative urine culture. EKG sinus 
rhythm, Rx chest normal, cranial CT normal.
Discussion
The serotonin syndrome for associating tramadol 
plus paroxetine plus mirtazapine was a diagnosis of 
exclusion in the absence of evidence of infectious, 
metabolic or ischemic causes. It was decided to discon-
tinue tramadol and mirtazapine and paroxetine was 
gradually lowered. Parenteral hydration was initiated 
with 1500 ml/24 hours. The patient was treated with 
midazolam at low doses (10 mg/24 hours) and 4 days 
after starting this treatment she began to improve. The 
delirium reverted and the clonus remitted. The blood 
pressure and heart rate normalized. Good analgesia 
was achieved with low doses of subcutaneous mor-
phine (15 mg/24 hours).
The prevalence of serotonin syndrome caused by 
tramadol is unknown, however between 1997 and 
2017 968 cases of serotonin syndrome were reported 
to the FDA, 98 of which died [5]. The true incidence 
of serotonin syndrome is not known because it is not 
reported. This lack of notification has many reasons: 
the manifestations are usually falsely attributed to 
other causes, in moderate cases most of the clinicians 
do not suspect it, and in a study done among doctors 
85% did not know this diagnosis [5].
The serotonin syndrome is diagnosed clinically 
by anamnesis and physical examination. The Hunter 
criteria can help; they have 84% sensitivity and 97% 
specificity. The patient must have taken a  seroto-
nergic agent and show one of the following signs: 
spontaneous clonus, inducible clonus with agitation 
or diaphoresis, ocular clonus with agitation or diapho-
resis, ocular clonus with hypertonia and hyperthermia 
and/or tremor with hyperreflexia (Table 1) [4, 5].
Serotonin syndrome includes a  classic triad of 
neuromuscular hyperactivity, autonomic hyperactivity 
and delirium. Moderate cases present with nonspecific 
symptoms such as nervousness, insomnia, nausea, 
tachycardia, abdominal pain and it is often under-
diagnosed and undertreated [5]. In mild cases, as in 
the present case, patients present with mild hyper-
tension and tachycardia with some combination of 
mydriasis, diaphoresis, shivering, tremor, myoclonus, 
and hyperreflexia. In severe cases, hyperthermia is 
greater than 41°C with delirium and muscle rigidity. 
Severe cases may result in coma and death by many 
complications, such as seizures, rhabdomyolysis, my-
oglobinuria, metabolic acidosis, renal failure, acu-
te respiratory distress syndrome, respiratory failure, 
and diffuse intravascular clotting [4, 5]. It has been 
reported frequently when associating tramadol with 
other drugs such as fluoxetine, paroxetine, sertrali-
ne, venlafaxine, citalopram and bupropion. This is 
also a problem if tramadol is co-administered with 
monoamine oxidase inhibitors and some atypical an-
tipsychotics [4, 5]. In this patient who was receiving 
paroxetine and mirtazapine, the serotonin syndrome 
manifested when tramadol was added. To be able to 
make the diagnosis, a complete and thorough medical 
history is necessary.
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Table 1. Symptoms of serotonin syndrome
Serio-
usness
Autonomic signs Neurological Signs Mental status Other
Mild • Afebrile or low-grade 
fever
• Tachycardia
• Mydriasis
• Diaphoresis or shive-
ring
• Intermittent tremor
• Akathisia
• Myoclonus
• Mild hyperreflexia
• Restlessness
• Anxiety
Moderate • Increased Tachycardia
• Fever (40ºC)
• Diarrhoea with hype-
ractive bowel sounds
• Diaphoresis with nor-
mal skin colour
• Hyperreflexia
• Inducible clonus
• Ocular clonus (slow 
continuous lateral eye 
movements)
• Myoclonus
• Easily startled
• Increased con-
fusion
• Agitation and 
hypervigilance
• Rhabdomyolysis
• Metabolic acidosis
• Renal failure
• Disseminated Intravascular 
coagulopathy (secondary 
to hyperthermia)
Severe • The temperature 
often more than 41ºC 
(secondary to incre-
ased tone)
• Increased muscle tone 
(lower limb > upper)
• Spontaneous clonus
• Substantial myoclo-
nus or hyperreflexia
• Delirium
• Coma
• As above
The prevention of serotonin syndrome begins by 
sensitizing physicians to be able to recognize early 
the first signs and symptoms of serotonin toxicity and 
suspend the precipitating agents. Most physicians 
are aware of serotonin syndrome secondary to an-
tidepressants but do not think of other drugs such as 
analgesics. Tramadol has an analgesic effect that does 
not exceed moderate and there is no robust evidence 
for its use. The aforementioned adverse effects require 
prudent use or prescription should even be avoided [5].
In the treatment of cancer–related pain, the second 
step of the WHO analgesic ladder is under questioning 
since the criticism that is given is the definitive absence 
of proven efficacy of “weak” opioids. A meta-analysis 
of randomized trials showed no significant differences 
between non-opioid analgesics alone or non–opioids 
combined with opioids. A Cochrane review on the use 
of tramadol in the treatment of cancer-related pain, 
which included 10 studies with 958 participants, stated 
that there is limited, very low quality of evidence from 
randomised controlled trials that tramadol produced 
pain relief in some adults with pain due to cancer and 
no evidence at all in children; the place of tramadol in 
managing cancer pain and its role as step 2 opioid of the 
WHO analgesic ladder is unclear [6]. Given these data 
on the doubtful efficacy of tramadol in treatment of 
oncological pain, many authors have proposed the abo-
lition of the second step of the WHO analgesic ladder, 
in favour of the early use of morphine in low doses [7].
Conclusions
Concurrent administration of tramadol with SSRIs 
or SNRIs appears to increase the risk of serotonin 
syndrome. In patients who may require higher doses 
of tramadol, it would be reasonable to avoid the 
combinations [4, 5]. Until there is a  substantial 
body of evidence of either benefit or harm, doc-
tors will continue to prescribe tramadol based on 
personal preference rather than clinical evidence. 
Mechanistically, tramadol does have some appealing 
properties, despite adverse effects, so cautious use, 
starting with a small dose and careful titration are 
suggested. 
Henry Marsh, in his book “Do no harm”, describes 
the complex calculation involved in decision making, 
always weighing the possibility of treating patients in 
the face of the danger of aggravating their situation; 
put on one side of the scale the knowledge and 
experience and, on the other, the risks. We can ad-
mit that the iatrogenic damage is not avoidable in 
absolute terms, but it is in relative terms, and it is 
convenient to analyse what can be done to reduce it 
to the minimum.
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